Key facts
- It has raised $13.3M; the latest was Later Stage VC ($13.0M) in Aug 2025.
- Notable investors include National Institutes of Health, University of California, California Institute for Regenerative Medicine, Los Angeles, Magnify — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for MAX BioPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for MAX BioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MAX BioPharma
Developer of novel small-molecule lipids designed to provide treatments for fatal and debilitating disorders. The company develops oxysterols that can stimulate bone growth and block cancer cell growth as well as inhibit their ability to metastasize, enabling doctors to treat pancreatic cancer, breast cancer, and hematologic malignancies.
- Sector
- Healthcare
- HQ
- Santa Monica, CA, United States
- Founded
- 2010
- Employees
- 5
- Website
- maxbiopharma.com/
- Ownership
- Privately Held (backing)
MAX BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MAX BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MAX BioPharma in its N-PORT filings yet. We sweep new filings monthly.